{"id":"NCT01955161","sponsor":"H. Lundbeck A/S","briefTitle":"Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With Donepezil","officialTitle":"Randomised, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With Donepezil","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-10","primaryCompletion":"2016-07","completion":"2016-07","firstPosted":"2013-10-07","resultsPosted":"2017-09-19","lastUpdate":"2017-09-19"},"enrollment":933,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Alzheimer's Disease"],"interventions":[{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Idalopirdine","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Idalopirdine 30 mg","type":"EXPERIMENTAL"},{"label":"Idalopirdine 60 mg","type":"EXPERIMENTAL"}],"summary":"To establish efficacy of idalopirdine as adjunctive therapy to donepezil for symptomatic treatment of patients with mild-to-moderate Alzheimer's disease (AD).","primaryOutcome":{"measure":"Change in Cognition","timeFrame":"Baseline to Week 24","effectByArm":[{"arm":"Placebo","deltaMin":0.13,"sd":0.35},{"arm":"Idalopirdine 30 mg","deltaMin":0.47,"sd":0.35},{"arm":"Idalopirdine 60 mg","deltaMin":0.18,"sd":0.35}],"pValues":[{"comp":"OG000 vs OG001","p":"0.9591"},{"comp":"OG000 vs OG002","p":"1.000"}]},"eligibility":{"minAge":"50 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":5},"locations":{"siteCount":137,"countries":["United States","Argentina","Belgium","Bulgaria","Canada","Chile","Czechia","Denmark","France","Germany","Italy","Poland","Romania","South Africa","Spain","Ukraine"]},"refs":{"pmids":["31193334","30474567","29318278"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":12,"n":308},"commonTop":["Accidental overdose","Fall","Gamma-glutamyltransferase increased"]}}